Last $123.28 USD
Change Today -0.62 / -0.50%
Volume 836.0K
LH On Other Exchanges
Symbol
Exchange
Berlin
New York
As of 8:04 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

laboratory crp of amer hldgs (LH) Key Developments

Laboratory Corp. of America Holdings Announces Dividend for 2014, Payable on 22 May 2015

Laboratory Corp. of America Holdings announced the dividend payment from 2014 operating results to shareholders at the rate of THB 0.38 per share or amounting to THB 1,829,417,753.10, of which the company has paid an interim dividend at the rate of THB 0.19 per share or amounting to THB 914,708,876.55 on September 5, 2014, and will pay the remaining dividend at the rate of THB 0.19 per share or amounting to THB 914,708,876.55 to the shareholders, by setting the record date on 7 May 2015 to determine the shareholders entitled to receive dividend, and the shareholders register book closing date on 8 May 2015 on which the shareholder list as specified in section 225 of the Securities and Exchange Act shall be complied. The dividend payment shall be paid on 22 May 2015.

Laboratory Corp. of America Holdings Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015

Laboratory Corp. of America Holdings announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company's sales were approximately $1.51 billion, an increase of 5.3% over last year's $1.44 billion. The increase in sales was the result of volume, measured by requisitions, and acquisitions, partially offset by price, mix and currency. The growth in revenue was due to organic volume of 5.3%, partially offset by a decline in revenue per requisition of 1.1% and negative impact of currency of 0.5%. Operating income for the quarter was $219.0 million, compared to $215.0 million in the fourth quarter of 2013. Adjusted operating income for the quarter was $234.6 million, compared to $219.0 million in the fourth quarter of 2013. The increase in adjusted operating income was due to increased volume, partially offset by personnel expense, core testing growth outpacing esoteric testing growth and less revenue generated from uninsured patients. Net earnings attributable to the company for the quarter were $119.6 million or diluted EPS were $1.39, compared to last year's earnings of $126.3 million or $1.43, respectively. Adjusted EPS were $1.65 in the fourth quarter, compared to $1.61 in the fourth quarter of 2013. Operating cash flow for the quarter was $213.7 million, compared to $248.7 million in the fourth quarter of 2013, as the company used working capital to support its strong revenue growth, and incurred cash costs relating to Project LaunchPad and the Covance acquisition. Capital expenditures totaled $46.3 million, compared to $59.6 million in the fourth quarter of 2013. Earnings before income taxes were $187.5 million compared with $194.2 million a year ago. Free cash flow, or operating cash flow after capital expenditures, was $167 million compared to $189 million last year. For the year, the company's sales were approximately $6.01 billion, an increase of 3.5% over last year's $5.81 billion. The increase in sales was the result of volume, measured by requisitions, and acquisitions, partially offset by price, mix and currency. The growth in revenue was due to organic volume of 3.5%, partially offset by a decline in revenue per requisition of 1.4% and negative impact of currency of 0.4%. Operating income for 2014 was $910.4 million, compared to $990.9 million in 2013. Adjusted operating income for the year was $951.6 million, compared to $1,012.7 million in 2013. Net earnings attributable to the company for 2014 were $511.2 million or diluted EPS were $5.91, compared to last year's earnings of $573.8 million or $6.25, respectively. Adjusted EPS were $6.80 in 2014, compared to $6.95 in 2013. Operating cash flow for 2014 was $739.0 million, compared to $818.7 million in 2013, primarily due to lower net earnings, Project LaunchPad and working capital to support strong revenue growth. Capital expenditures totaled $203.5 million, compared to $202.2 million in 2013. Earnings before income taxes were $826.7 million compared with $915.6 million a year ago. For 2015, the company's total revenue growth of approximately 40% to 44%, after adjusting for approximately 160 basis points of negative currency impact. The company expects adjusted EPS of $7.35 to $7.70, an increase of approximately 8% to 13% against the prior year, which includes accretion of approximately $0.35 to $0.40 to earnings in 2015 from the acquisition of Covance. The company expects operating cash flow of $1,075 million to $1,100 million, with capital expenditures between $325 million and $350 million. As a result, free cash flow is between $725 million and $775 million, an increase from $536 million in 2014. In 2015, the company expects interest and amortization expense to be approximately $220 million and $165 million respectively. The company expects the tax rate to be approximately 35%.

Laboratory Corp. of America Mulls Acquisitions

Laboratory Corp. of America Holdings (NYSE:LH) is looking for acquisitions. David P. King, Chairman and Chief Executive Officer of Laboratory Corp. of America said, "Free cash flow will be used to pay down debt and for tuck-in acquisitions".

Laboratory Corp. of America Holdings to Report Q4, 2014 Results on Feb 20, 2015

Laboratory Corp. of America Holdings announced that they will report Q4, 2014 results Pre-Market on Feb 20, 2015

Laboratory Corp. of America Holdings, Q4 2014 Earnings Call, Feb 20, 2015

Laboratory Corp. of America Holdings, Q4 2014 Earnings Call, Feb 20, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LH:US $123.28 USD 0.00

LH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cerner Corp $72.51 USD +0.61
PAREXEL International Corp $66.36 USD +2.07
QIAGEN NV €22.87 EUR +0.55
Quest Diagnostics Inc $72.31 USD +0.54
Sonic Healthcare Ltd A$19.75 AUD -0.10
View Industry Companies
 

Industry Analysis

LH

Industry Average

Valuation LH Industry Range
Price/Earnings 20.9x
Price/Sales 1.7x
Price/Book 3.7x
Price/Cash Flow 21.1x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LABORATORY CRP OF AMER HLDGS, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.